Nanoform and Aprecia Explore 3D-Printed Drug Dosage Forms
The collaboration will evaluate Nanoform’s fast dissolution nanoparticles in Aprecia’s ZipDose 3DP technology platform for buccal and oral drug delivery.
Nanoform Finland and Aprecia announced in an April 21, 2021 press release that they are investigating potential synergies between their technologies, with the goal of providing new capabilities for patient-centric therapies in oral and buccal drug-delivery. The companies are combining Nanoform’s fast dissolution, nanoformed particles with Aprecia’s ZipDose three-dimensional printing (3DP) technology platform, which allows rapid disintegration. These features can enable rapid absorption, as well as lower dosage products, less excipient content, and reduced pill burden.
“This is [an] opportunity to demonstrate the power of small for rapid drug absorption, potentially bypassing the first-pass metabolism via a novel dosage form, such as buccal delivery, with Aprecia’s 3DP technology platforms,” said Edward Hæggström, CEO of Nanoform, in the press release.
“Aprecia’s proprietary 3DP technology platforms are focused on providing solutions to our partner’s toughest formulation challenges that can’t be achieved through conventional manufacturing technologies,” added Chris Gilmore, CEO of Aprecia, in the press release.
Source: Nanoform
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
